Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. - sprookjes - yvandenbroek - TriplyDB

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

http://www.wikidata.org/entity/Q37309080

about

Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.Hepatitis C virus: how to provide the best treatment with what I have.Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials.Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis.Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis.Impact of Viral Etiology on Postoperative De Novo Recurrence After Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Patients.Urgency to treat patients with chronic hepatitis C in Asia.Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.Clinical Pharmacokinetics of Paritaprevir.Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir.Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy.A comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b.Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016."Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline.Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease.The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation.Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.

P2860

Q26775825-B01DEE70-1379-496E-899F-8F9D290FA2E3 Q28075544-F9193403-151B-41F1-AD4C-E08DC4A6B5E0 Q33582978-40042B66-204C-4DEB-A4DE-ABAF36966953 Q36146807-8C8324B1-2B7F-4DED-BE1D-4B36B0FEE23E Q36173242-5130AD95-38AC-4C62-BFE7-F6CD7B3016C5 Q36335281-2A0E11E4-D38F-4C55-89BA-F8993985254E Q36519126-39637922-4AFB-49F6-B531-5F4382928573 Q37612271-3689995F-255A-4C0A-9DBE-6169A65336BF Q37710140-98BD2E23-DD0A-456F-A254-6D6D36D8A6DA Q37743001-8D02E14A-A655-49EE-AAA7-EE4BB53B95A8 Q38367590-2F01878E-C0F2-4B28-B7B8-D865C4222331 Q38376454-D69AD693-FF05-45AF-9E42-2D1487064AD1 Q38393581-94A19377-1000-41F9-BD76-78EEB0B21F0C Q38398290-022D1BCD-BDC7-4DAC-9B0B-2B7C4BFCD4EA Q38685580-4508DCBA-8978-4774-8B14-B9EB7713DF3B Q38837174-B04B8410-A113-4901-A6FE-2AEB0F46211C Q38903835-7EF09A86-4F36-4962-9A1C-EC747A566479 Q38974653-10CA2C42-7600-4380-84E8-4F6EB8A17C6A Q39041689-4F47A75C-3D08-4F78-BEA9-700E420D4131 Q39049155-7D8094A4-4FA0-4417-B003-8B93586B125A Q39104215-8AD13515-3848-4423-A65E-8DCB08BF09E6 Q39150134-721F5C6F-C34D-4C75-BC04-FFFB04181259 Q39483711-1FA6A0E6-13C6-4CB3-9EC4-FE6EAF34F486 Q39675766-58F1E1C8-FEB4-47F5-9FD4-4FE982F33431 Q40041670-CBE0CD85-1DD9-44DF-9038-DFA4510ECF70 Q40058097-BDA2AD5A-FB30-42F8-A366-097BCB19320D Q40069650-D7A3E884-FEF8-4363-8496-E875312879B6 Q40087272-0D2A2EFC-B23A-4699-9B6A-509DAE9E351E Q40130081-654BF41F-724E-47E6-B3B9-D8491527ADE2 Q40148468-082F0A2D-21FC-43B6-BA67-F2BC4376301F Q40228836-4AE2A67B-D32E-498F-B0C3-CBAFD41C912F Q40292229-3415D45D-BD32-4347-9E2B-679F96D3463E Q40317327-18132E15-FCD1-4483-8098-09C20D4AABE9 Q40323892-E42813C1-3721-4C1D-85E9-9EC2A26A9DCB Q40340001-81D3ED4C-2138-463D-8DEA-E85D03491A8A Q40400190-ADAA7F7B-FA8D-4C7D-BEF7-1B694E55636C Q40409263-96F2F81A-09C7-4EB9-BABF-EEBEE91E08F7 Q40489570-0EB8E8FD-4EC0-49A5-9A38-570B88A1BC65 Q40533002-F86A2B65-EAFF-4A96-9B95-855B6C92F6D5 Q40583906-D474B8E4-D16C-4483-B437-CFB453A93BD2

P2860

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

http://www.wikidata.org/entity/Q37309080

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 July 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Randomized phase 3 trial of om ...... nts with or without cirrhosis.

@en

Randomized phase 3 trial of om ...... nts with or without cirrhosis.

@nl

type

label

Randomized phase 3 trial of om ...... nts with or without cirrhosis.

@en

Randomized phase 3 trial of om ...... nts with or without cirrhosis.

@nl

prefLabel

Randomized phase 3 trial of om ...... nts with or without cirrhosis.

@en

Randomized phase 3 trial of om ...... nts with or without cirrhosis.

@nl

P1433

Q37309080-F5508BB6-2B90-4123-8D80-9D9121968529

P1476

Q37309080-CEA38F8C-C851-4C4A-9B61-96CBB8F51607

P2093

Q37309080-05385189-1884-4DDE-B24D-443CBEF2A0DD

Q37309080-11EC5515-55CE-4AAB-9AC4-BDC1812535DD

Q37309080-6139D941-1861-4E20-88A5-230F5C2CD587

Q37309080-63D5CFBF-AAB9-4E69-9245-A499A68CB538

Q37309080-68BCDFAD-649D-4494-90CC-B3834A82742A

Q37309080-7F93C85F-BA8F-4EE6-925D-6C3F207FFFE0

Q37309080-822FEA67-7099-4FF4-BB99-C34A97CEF568

Q37309080-9CE3D41B-C187-401A-B9C4-B66E3CCE81D9

Q37309080-A4818FC2-ECF6-4135-9B33-75B094E06C3A

Q37309080-BAC8B192-28BC-461C-8751-FA217DDFF821

P2860

Q37309080-0241429D-0182-4451-9DB7-BABE81D03154

Q37309080-07BAB1B4-0E68-4D65-AD6B-639FF16F9FD7

Q37309080-23AC77AA-C69C-4EA3-8B89-6267BDF67ABD

Q37309080-24415427-103B-44B6-ADFC-469F1EE487D8

Q37309080-25216B5B-BD47-4E62-95A3-D46A739256E1

Q37309080-2649528F-F8BB-482E-9146-CF8ACD21EA6A

Q37309080-27181980-DE2B-400D-8F52-640EC5BD7F48

Q37309080-28137615-61B7-4B7C-A767-13E1BABC9A4C

Q37309080-32AA7C46-67C9-4FD1-8E7F-5FD5D8DFB67E

Q37309080-6426903E-4F40-4DF2-9245-9AE48D878FF0

P304

Q37309080-7051D224-DE26-466B-BAAE-CB056CD2AB11

P31

Q37309080-82659612-69D4-48DA-93E1-FD2380A65A3A

P356

Q37309080-7C309CD1-0B6F-4B7E-9ABD-F899C4DEBAB7

P407

Q37309080-7C4DCE14-E6DD-4686-822B-3A7AD15C70DC

P433

Q37309080-52DC944E-6DE0-4815-8E1B-F59875EE6CB9

P478

Q37309080-DDA09D80-46E0-4A75-9634-2A708288D77D

P50

Q37309080-0075C3E0-4EA1-4AAD-B502-F05BDF2A86CB

Q37309080-CCF98B2A-7502-42B2-922A-B9D20EE0287F

P577

Q37309080-92FBEC92-546A-4846-8E35-BB2478C8E5E1

P698

Q37309080-C1393385-69B6-4FE6-9A1B-1E52E2C4FE58

P921

Q37309080-076916A3-2663-4DA1-9998-448C758CE262

Q37309080-33447DF0-8968-44F9-80F3-56AE0839CAB7

Q37309080-B169E322-26E3-40C2-9E5B-3D2DE4585CDA

Q37309080-F50AF8AD-AE14-4D1C-9768-93A31C1A88D6

P932

Q37309080-AD494F97-11A6-4CD1-BF65-84FC44AF1BC4

P356

P1433

P1476

Randomized phase 3 trial of om ...... nts with or without cirrhosis.

@en

P2093

Carolyn Setze

http://www.w3.org/2001/XMLSchema#string

Fumitaka Suzuki

http://www.w3.org/2001/XMLSchema#string

Hidenori Toyoda

http://www.w3.org/2001/XMLSchema#string

Hiromitsu Kumada

http://www.w3.org/2001/XMLSchema#string

Kazuaki Chayama

http://www.w3.org/2001/XMLSchema#string

Ken Sato

http://www.w3.org/2001/XMLSchema#string

Kenji Ikeda

http://www.w3.org/2001/XMLSchema#string

Kiyohide Kioka

http://www.w3.org/2001/XMLSchema#string

Lino Rodrigues

http://www.w3.org/2001/XMLSchema#string

Margaret Burroughs

http://www.w3.org/2001/XMLSchema#string

P2860

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Acute hyperglycemia worsens hepatic ischemia/reperfusion injury in rats.

Glucose intolerance and serum aminotransferase activities in Japanese men.

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Changing trends in hepatitis C infection over the past 50 years in Japan.

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.

The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay.

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

P304

1037-1046

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.27972

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

Tami Pilot-Matias

P577

2015-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26147154

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

phase III clinical trial

P932

5049673

http://www.w3.org/2001/XMLSchema#string